Capricor Therapeutics Faces Securities Class Action After Major Stock Drop

Capricor Therapeutics Faces SEC Class Action

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently embroiled in a securities class action following a shocking plunge in its stock value. The firm Levi & Korsinsky, LLP has alerted investors of a lawsuit filed on behalf of shareholders who purchased securities from December 17, 2025, to July 26, 2026.

The Price Collapse Explained

Recent reports indicated that Capricor’s shares plummeted from an impressive $19.70 to a mere $4.19. The drastic fall of approximately 78.7%, or an aggregate loss of $15.08 per share, occurred amid unfriendly FDA briefing documents and an adverse advisory committee vote. These developments resulted in two significant corrective disclosures, which sent shockwaves through the financial market.

After closing at $7.00 on July 27, 2026—a staggering drop of 64%—the stock further declined to $4.19 on July 30, 2026. A comparison to the stock's peak at $35.34 on April 21, 2026, reveals that investors have faced cumulative losses over $31 per share.

Timeline of Events

Just prior to the decline, the FDA disclosed critical briefing documents ahead of its advisory committee meeting regarding the deramiocel Biologics License Application (BLA). The documents revealed that the HOPE-3 study did not meet its efficacy endpoints, prompting concerns about the treatment's viability. Following this, the advisory committee voted 9-3 against supporting deramiocel for treating DMD-associated cardiomyopathy, causing a further market downturn.

Joseph E. Levi, Esq., representing investors, noted that the swift and significant repricing raises questions regarding whether investors were privy to essential information about the trial's data analysis. The lawsuit claims that key details about the statistical analysis plan were not disclosed until after the FDA published its evaluation.

Key Details of the Class Action

This class action could represent investors who engaged in stock transactions during the outlined period. Potential plaintiffs are urged to act quickly, as the deadline for seeking lead plaintiff status is September 28, 2026. The complaint underscores that investors were misled concerning changes to the pre-specified statistical analysis plan, significantly heightening approval risks when shares were trading at artificially inflated values.

Important Information for Investors

Investors should compile brokerage records indicating purchase dates, share quantities, and prices paid. The law firm is providing a no-obligation evaluation of potential cases, allowing interested parties to determine their eligibility for compensation related to losses incurred during this tumultuous period.

The class action was filed in the United States District Court for the Southern District of California, under the aegis of the Private Securities Litigation Reform Act of 1995. Levi & Korsinsky has built a reputation over 20 years for advocating for shareholders' rights, having successfully recovered hundreds of millions of dollars for aggrieved investors.

For those wondering about participation requirements, there's no upfront cost. The class action operates on a contingency basis, assuring that investors bear no immediate fees. Thus, even if shares were sold, investors can still seek to recover losses incurred during the class period.

Conclusion

As this unfolding situation develops, shareholders are strongly encouraged to remain informed and proactive. The outcome of this class action could have significant ramifications for Capricor Therapeutics and its investors. Attention to key updates regarding this case is vital for all affected shareholders.

For further inquiries or to explore your options as a potential class member, contact Levi & Korsinsky,
Email: [email protected]
Phone: (212) 363-7500.

This situation serves as a reminder of the importance of transparency in the financial markets and the rights of investors seeking redress for their losses.